Relationship Between ANCA-Associated Vasculitis and Infection: A Review

  • Yingxue Zhou The First Affiliated Hospital of Chongqing Medical University
  • Qing Shen The First Affiliated Hospital of Chongqing Medical University
Keywords: ANCA, Infection, Pathogenesis, Complications

Abstract

ANCA-associated vasculitis (AAV) is an autoimmune disease with multiorgan involvement of the entire body. And infection has been paid more and more attention in the course of treatment. As far as the current research is concerned, infection participates in the pathogenesis of AAV, interferes with the treatment of AAV, and affects the prognosis of AAV. This paper focuses on the role of pathogen infections in AAV pathogenesis. This review also elaborates on the types and prognosis of secondary infections in AAV patients. According to the current study, maintaining an appropriate BMI and vaccination is beneficial to the prevention of infection and the prognosis of AAV patients.

References

[1] Jennette J, Falk R, Bacon P, et al. 2012 Revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides[J]. Arthritis & Rheumatology, 2012, 20(1).

[2] Mohammad AJ. An update on the epidemiology of ANCA-associated vasculitis. Rheumatology (Oxford). 2020 May 1;59(Suppl 3):iii42-iii50.

[3] Silva F, Specks U, Sethi S, et al. Successful Pregnancy and Delivery of a Healthy Newborn Despite Transplacental Transfer of Antimyeloperoxidase Antibodies From a Mother With Microscopic Polyangiitis[J]. American Journal of Kidney Diseases, 2009, 54(3): 542-545.

[4] Falk RJ, Terrell RS, Jennette L, et al. Anti-Neutrophil Cytoplasmic Autoantibodies Induce Neutrophils to Degranulate and Produce Oxygen Radicals in vitro[J]. Proceedings of the National Academy of Sciences of the United States of America, 1990, 87(11):4115-4119.

[5] Jennette JC, Falk RJ. ANCAs Are Also Antimonocyte Cytoplasmic Autoantibodies[J]. Clinical Journal of the American Society of Nephrology Cjasn, 2014, 10(1):4-6.

[6] Kain R, Exner M, Brandes R, et al. Molecular mimicry in pauci-immune focal necrotizing glomerulonephritis[J]. Nature Medicine, 2008, 14(10): 1088-1096.

[7] Pendergraft WF, Preston GA, Shah RR, et al. Autoimmunity is triggered by cPR-3(105-201), a protein complementary to human autoantigen proteinase-3.[J]. Nature Medicine, 2004, 10(1):72-79.

[8] Stegeman CA, Tervaert JW, Sluiter WJ, et al. Association of Chronic Nasal Carriage of Staphylococcus aureus and Higher Relapse Rates in Wegener Granulomatosis[J]. Ann Int Med, 1994, 120(1):12-17.

[9] Salmela A, Rasmussen N, Tervaert JWC, et al. European Vasculitis Study Group. Chronic nasal Staphylococcus aureus carriage identifies a subset of newly diagnosed granulomatosis with polyangiitis patients with high relapse rate. Rheumatology (Oxford). 2017;56(6):965-972.

[10] Li H, Nooh MM, Kotb M, et al. Commercial peptidoglycan preparations are contaminated with superantigen-like activity that stimulates IL-17 production[J]. Journal of Leukocyte Biology, 2008, 83(2): 409-418.

[11] Oukka, M. Th17 cells in immunity and autoimmunity[J]. Annals of the Rheumatic Diseases, 2008, 67 Suppl 3(Suppl 3):986789-986789.

[12] Bhattacharya M, Berends ETM, Chan R, et al. Staphylococcus aureus biofilms release leukocidins to elicit extracellular trap formation and evade neutrophil-mediated killing. Proc Natl Acad Sci U S A. 2018;115(28):7416-7421.

[13] Nakazawa D, Masuda S, Tomaru U, et al. Pathogenesis and therapeutic interventions for ANCA-associated vasculitis [published correction appears in Nat Rev Rheumatol. 2019 Jan 17;:]. Nat Rev Rheumatol. 2019;15(2):91-101.

[14] Sfriso P, Ghirardello A, Botsios C, et al. Infections and autoimmunity: the multifaceted relationship. J Leukoc Biol. 2010;87(3):385-395.

[15] Henderson LA, Canna SW, Schulert GS, et al. On the alert for cytokine storm: Immunopathology in COVID-19[J]. Arthritis & Rheumatology, 2020, 72(7).

[16] Caas CA . The triggering of post-COVID-19 autoimmunity phenomena could be associated with both transient immunosuppression and an inappropriate form of immune reconstitution in susceptible individuals[J]. Medical Hypotheses, 2020, 145:110345.

[17] Mcgregor J, Negrete-Lopez R, Poulton C J, et al. Adverse events and infectious burden, microbes and temporal outline from immunosuppressive therapy in antineutrophil cytoplasmic antibody-associated vasculitis with native renal function[J]. Nephrology Dialysis Transplantation, 2015, 30(suppl_1): i171-i181.

[18] Thomas K, Argyriou E, Kapsala N, et al. Serious infections in ANCA-associated vasculitides in the biologic era: real-life data from a multicenter cohort of 162 patients[J]. Arthritis Research & Therapy, 2021, 23(1):1-9.

[19] Kidney Disease: Improving Global Outcomes (KDIGO) Blood Pressure Work Group. KDIGO 2021 Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease. Kidney Int. 2021 Mar;99(3S):S1-S87.

[20] Yang L, Xie H, Liu Z, et al. Risk factors for infectious complications of ANCA-associated vasculitis: a cohort study[J]. Bmc Nephrology, 2018, 19(1):1-7.

[21] Lai QY, Ma TT, Li ZY, et al. Predictors for mortality in patients with antineutrophil cytoplasmic autoantibody-associated vasculitis: a study of 398 Chinese patients.[J]. Journal of Rheumatology, 2014, 41(9):1849-55.

[22] Kronbichler A, Kerschbaum J, Gopaluni S, et al. Trimethoprim-sulfamethoxazole prophylaxis prevents severe/life-threatening infections following rituximab in antineutrophil cytoplasm antibody-associated vasculitis. Ann Rheum Dis. 2018;77(10):1440-1447.

[23] Furer V, Rondaan C, Heijstek MW, et al. 2019 update of EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases. Ann Rheum Dis. 2020;79(1):39-52.

[24] Sugiyama H, Yamaguchi M, Katsuno T, et al. Association between body mass index and severe infection in older adults with microscopic polyangiitis: a retrospective cohort in Japan[J]. BMC Geriatrics, 2021, 21(1):1-10.
Published
2023-03-21
Section
Original Research Article